Interestingly, in colorectal cancer it has been recently described that tumour-derived LILRB2 promotes tumour growth by increasing angiogenesis, and its blocking sensitises tumours to bevacizumab (anti-VEGF-A) treatment (163). Here, VEGFA is linked to neoplasm.